|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 324.80 SEK | +2.27% |
|
-1.04% | +4.50% |
| 08/05 | US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy | MT |
| 08/05 | Futures point to negative opening for Stockholm Stock Exchange (update) | FW |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 5 | |||||||
| 23 | |||||||
| 27 | |||||||
| 20 | |||||||
| 20 | |||||||
| 23 | |||||||
| - | - | 7 | |||||
| 23 | |||||||
| 14 | |||||||
| 12 | |||||||
| 7 | |||||||
| 14 | |||||||
| 17 | |||||||
| 15 | |||||||
| 15 | |||||||
| - | - | ||||||
| 10 | |||||||
| 11 | |||||||
| 22 | |||||||
| Average | 16 | |||||||
| Weighted average by Cap. | 19 |
- Stock Market
- Equities
- BIOA B Stock
- Sector BioArctic AB
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition